Vanderbilt University Medical Center’s Acute Myocardial Infarction, Discharged Alive MSPB average increased by almost 13% – Dexur

Vanderbilt University Medical Centers Acute Myocardial Infarction, Discharged Alive MSPB average increased by almost 13% Want a Demo of Dexur's full capabilities?

By: Parvathy Rajagopal  Oct. 16, 2020

Dexur analyzed Medicare Claims data and replicated CMS algorithms to calculate Medicare Spending per Beneficiary (MSPB) cost per episode of Vanderbilt University Medical Center and found that the cost per episode was $33,526 for Acute Myocardial Infarction, Discharged Alive, from Jan-Dec 2019. The cost increased by 12.55% in 2019 to reach $33,526 compared to $29,788 in 2018. MSPB is the only measure under the Efficiency and Cost Reduction domain under the Value-Based Purchasing (VBP) Program and accounts for 25% of VBP adjustments.

The analysis was done at the DRG level to implement risk adjustment, specifically for DRG 280: Acute Myocardial Infarction, Discharged Alive with Major Complication or Comorbidity. The data is further fragmented at the DRG group level and for specific DRGs within the group as well, to generate a layered analysis of all claims involved, such as Index hospitalization, rehospitalization, SNFs, HHAs, and Hospice. Reducing the overall MSPB episode cost by targeting specific DRGs with higher averages will improve inpatient care and stabilize financial footing.

Post-discharge costs are the predominant cost contributors per MSPB episode. For the Jan-Dec 2018 period, the post-discharge cost share was $12,494, amounting to 42% of the total share. Rehospitalization was the highest post-discharge cost contributor at $8,578. For the current time period, Jan-Dec 2019, the post-discharge cost rose to 56% of the total cost, adding $18,973 to the cost per episode. Rehospitalization saw a decrease of 2.8% over a 12 month rolling time period to reachat $8,338.

Continued here:
Vanderbilt University Medical Center's Acute Myocardial Infarction, Discharged Alive MSPB average increased by almost 13% - Dexur